Literature DB >> 20033409

High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study.

Carlo L Balduini1, Luigi Gugliotta, Mario Luppi, Luca Laurenti, Catherine Klersy, Carla Pieresca, Gerlando Quintini, Francesco Iuliano, Rossana Re, Pierangelo Spedini, Nicola Vianelli, Alfonso Zaccaria, Enrico Maria Pogliani, Roberto Musso, Enrico Bobbio Pallavicini, Giovanni Quarta, Piero Galieni, Alberto Fragasso, Gianluca Casella, Patrizia Noris, Edoardo Ascari.   

Abstract

Therapeutic plasma exchange (PE) is the accepted therapy for thrombotic thrombocytopenic purpura (TTP). Because not all patients achieve remission, other treatment modalities have been used in addition to PE, but no randomized clinical trial evaluated their efficacy. The aim of this multicentric study was to compare the effectiveness of standard- versus high-dose methylprednisolone as an adjunctive treatment to PE in the acute phase of TTP. Sixty patients with idiopathic TTP were randomized to receive methylprednisolone 1 mg/kg/die intravenous or 10 mg/kg/die for 3 days, thereafter, 2.5 mg/kg/die in addition to PE. Both dosages of steroids were well tolerated. At the end of induction therapy (day 23), the percentage of patients failing to achieve complete remission was significantly higher in the standard dose (16 of 30) than in the high-dose group (seven of 30). Also, the number of cases without a good response at day 9 and the number of deaths were higher in the standard-dose arm, but the differences did not reach the statistical significance. Results of present study indicate that the association of PE with high-dose instead of standard-dose steroids reduces the percentage of TTP patients that fail to achieve complete remission.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20033409     DOI: 10.1007/s00277-009-0877-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  24 in total

Review 1.  Thrombotic microangiopathies: a general approach to diagnosis and management.

Authors:  Donald M Arnold; Christopher J Patriquin; Ishac Nazy
Journal:  CMAJ       Date:  2016-10-17       Impact factor: 8.262

Review 2.  How I treat refractory thrombotic thrombocytopenic purpura.

Authors:  Farzana A Sayani; Charles S Abrams
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

3.  Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Spero R Cataland; Peter J Kourlas; Shangbin Yang; Susan Geyer; Leslie Witkoff; Haiwa Wu; Camila Masias; James N George; Haifeng M Wu
Journal:  Blood Adv       Date:  2017-10-23

4.  Unresponsive thrombotic thrombocytopenic purpura in critically ill adults.

Authors:  Eric Mariotte; Alice Blet; Lionel Galicier; Michael Darmon; Nathalie Parquet; Etienne Lengline; David Boutboul; Emmanuel Canet; Richard Traineau; Benoît Schlemmer; Agnès Veyradier; Elie Azoulay
Journal:  Intensive Care Med       Date:  2013-04-03       Impact factor: 17.440

5.  [Clinical analysis of 61 patients with thrombotic thrombocytopenic purpura].

Authors:  M J Shi; W B Gao; W F Huang; J H Zhu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-09-30

6.  Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) 2017 in Japan.

Authors:  Masanori Matsumoto; Yoshihiro Fujimura; Hideo Wada; Koichi Kokame; Yoshitaka Miyakawa; Yasunori Ueda; Satoshi Higasa; Takanori Moriki; Hideo Yagi; Toshiyuki Miyata; Mitsuru Murata
Journal:  Int J Hematol       Date:  2017-05-26       Impact factor: 2.490

7.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

Review 8.  Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura.

Authors:  Kathryn Dane; Shruti Chaturvedi
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 9.  Thrombotic microangiopathy and associated renal disorders.

Authors:  Thomas Barbour; Sally Johnson; Solomon Cohney; Peter Hughes
Journal:  Nephrol Dial Transplant       Date:  2012-07       Impact factor: 5.992

10.  Approach to management of thrombotic thrombocytopenic purpura at university of cincinnati.

Authors:  N Abdel Karim; S Haider; C Siegrist; N Ahmad; A Zarzour; J Ying; Z Yasin; R Sacher
Journal:  Adv Hematol       Date:  2013-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.